©

Cocrystal Technology
The selection of the solid form of an API has a significant effect on product performance. Polymorphs, hydrates, and salts are the commonly available options if a crystalline form is desired. Cocrystals present an additional option, and a very significant one if the API is non-ionizable or unable to form effective salts.

If the unique cocrystal properties can be leveraged to create the basis of a drug formulation that cannot be duplicated without the use of the cocrystal, the cocrystal patent will preserve market exclusivity beyond the expiration of the molecule patent or any FDA exclusivity.

Renovo's cocrystal screening technology is used to identify and establish new IP for new cocrystals of an API.

The improved cocrystal properties are used to develop a drug delivery mechanism that will create the product improvement.

Research by Renovo and for Renovo partners has resulted in a portfolio of cocrystal technology that is available for partnering/licensing.
The primary focus in most cocrystal projects is improving the solubility of a poorly soluble API. Especially for non-ionizable APIs or APIs that do not form salts, cocrystals represent a significant opportunity to identify crystalline forms with dramatically improved solubility and dissolution rate.

In addition to improving solubility, cocrystals can be used to reduce hygroscopicity, generate crystalline forms of non-crystalline materials, purify or resolve an API, or stabilize unstable molecules.

In situations that require amorphous, lyophylized, spray-dried, micro or nano-sized particles or similar extreme processing conditions, cocrystals may provide the required properties in a crystalline form that can perform as well or better without any additional processing.
2011 Renovo Research, LLC. All rights reserved.
+ Home
+ About
+ Contact
+ Alliances
Contact
About
Technology
Home
Alliances
+ Technology
Cocrystals can create improved physical properties
cocrystals of pharmaceuticals...